Prednisone or Prednisolone

Phase 3Small molecule

Prednisone or Prednisolone is one of 55 small molecule programs targeting Prostatic Neoplasms. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostatic NeoplasmsActive, not recruiting

Iga NephropathyActive, not recruiting

Cardiac SarcoidosisRecruiting

Prostatic NeoplasmsPhase 3

Active, not recruiting

Iga NephropathyPreclinical

Active, not recruiting

Cardiac SarcoidosisPhase 3

Recruiting

Competition

Competitive Landscape

43 competitors in Iga Nephropathy

#DrugCompanyPhaseTrials

Cellcept

Roche

Approved

7 2

Rituxan

Roche

Approved

2 3

Lorelco

Sanofi

Approved

1 4

Fabhalta

Novartis

Approved

—5

Velcade

SShilpa Grover, MD, MPH

Approved

1 6

Tekturna

Tibotec Pharmaceuticals, Ireland

Approved

1 7

Kerendia

Bayer

Phase 3

2 8

Farxiga

AstraZeneca

Phase 3

1 9

Filspari

TTravere Therapeutics, Inc.

Phase 3

2 10

Vanrafia

Novartis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Cardiac Sarcoidosis

NCT03593759

Q4 2027

Phase 3Active, not recruiting

Prostatic Neoplasms

NCT05288166

Clinical

Trials by Indication[1]

Prostate Cancer5 trials

A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT05295927·3 enrolled

Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer

Completed· Sanofi logo

Sanofi·Phase 3·NCT00519285·1,224 enrolled

A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

No longer available· Johnson & Johnson logo

Johnson & Johnson··NCT01834209

Show 2 more trials

Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT01972217·158 enrolled

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Completed· Sanofi logo

Sanofi·Phase 3·NCT01308580·1,200 enrolled

IgA Nephropathy1 trial

The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy

Completed·NNanjing University School of Medicine·N/A·NCT01451710·30 enrolled

Cardiac Sarcoidosis1 trial

Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial

Recruiting·OOttawa Heart Institute Research Corporation·Phase 3·NCT03593759·160 enrolled

Prostatic Neoplasms1 trial

CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT05288166·925 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Prednisone or Prednisolone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Prednisone or Prednisolone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Prednisone or Prednisolone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

Prednisone or Prednisolone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Trials by Indication[1]

Prostate Cancer5 trials

IgA Nephropathy1 trial

Cardiac Sarcoidosis1 trial

Prostatic Neoplasms1 trial

References

Drug Info

Quick Facts

Related News